Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2007;30(5):314-22.
doi: 10.1159/000106803. Epub 2007 Jul 11.

Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study

Bengt Fellström  1 , Hallvard Holdaas, Alan G Jardine, Helen Rose, Roland Schmieder, Wim Wilpshaar, Faiez Zannad; AURORA Study Group
Affiliations
Clinical Trial

Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study

Bengt Fellström et al. Kidney Blood Press Res. 2007.

Abstract

Background: Cardiovascular disease (CVD) is the leading cause of death in patients with end-stage renal disease (ESRD).

Aims: AURORA (A study to evaluate the Use of Rosuvastatin in subjects On Regular haemodialysis: an Assessment of survival and cardiovascular events) is the first large-scale international trial to assess the effects of statins on cardiovascular outcomes in patients with ESRD on chronic haemodialysis. Preliminary baseline data from the randomised population are presented.

Methods: A total of 2,775 patients from 280 centres in 25 countries were randomised into the study. Patients aged 50-80 years on regular chronic haemodialysis for at least 3 months before screening were eligible for inclusion. They were randomised 1:1 to receive either rosuvastatin 10 mg or placebo daily and assessed throughout the study.

Results: The mean age at baseline was 64 years. Most patients were male (62%) and 85% were white. The median time since commencing renal replacement was 32 months. Mean total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels were 4.53 mmol/l (175 mg/dl) and 2.57 mmol/l (99 mg/dl), respectively.

Conclusion: Results from the AURORA trial will impact on the current guidelines and use of statins in this patient population.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
AURORA study design. Adapted from Fellström et al. [32] (BioMed Central Open Access article).
Fig. 2.
Fig. 2.
Fig. 2. Prevalence of documented cardiovascular disease or risk equivalent at baseline. Y-axis truncated to 60% to improve the clarity of the data presented. Any = At least one cardiovascular disease or CVD risk equivalent; MI = myocardial infarction; CABG = coronary artery bypass graft; PAD = peripheral arterial disease; CAD = carotid artery disease; TIA = transient ischaemic attack.
See this image and copyright information in PMC

References

    1. Moeller S, Gioberge S, Brown G. ESRD patients in 2001: global overview of patients, treatment modalities and development trends. Nephrol Dial Tranplant. 2002;17:2071–2076. - PubMed
    1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events and hospitalization. N Engl J Med. 2004;351:1296–1305. - PubMed
    1. US Renal Data System Annual Data Report. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2005.
    1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32:S112–S119. - PubMed
    1. Parfrey PS. Cardiac disease in dialysis patients: diagnosis, burden of disease, prognosis, risk factors and management. Nephrol Dial Transplant. 2000;15(suppl 5):58–68. - PubMed